Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Checkmate completes $27mm Series B round

Executive Summary

Checkmate Pharmaceuticals Inc. (oncology) raised $27mm in its Series B round from new investor F-Prime Capital Partners (lead), along with returning backers Sofinnova and venBio. Proceeds will fund ongoing studies of CMP001, a CpG-A oligonucleotide therapeutic in Phase Ib trials in combination with pembrolizumab for melanoma, and will also support development of the candidate in additional potential indications.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies